LLY vs NVS
Eli Lilly and Novartis AG, both Healthcare
Eli Lilly is the larger company at $1.2T against $288B. Over the past year LLY returned +56% against +19% for NVS. The RyuScore puts NVS ahead, 75 against 60 out of 100.
| Figure | LLY | NVS |
|---|---|---|
| Last close | $1274 | $151 |
| Market cap | $1.2T | $288B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.8 | n/a |
| Dividend yield | 0.5% | n/a |
| 1-year return | +56% | +19% |
| 5-year return | +470% | +121% |
| RyuScoresector-relative, 1–10 | 60/100 | 75/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Eli Lilly
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.